View Older Stories View More Recent Stories

Oct 26, 2023 08:15AM Personalis (PSNL) Launches NeXT Personal Dx for Early Access Clinical Use
Oct 26, 2023 08:15AM Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
Oct 24, 2023 04:01PM Personalis to Announce Third Quarter 2023 Financial Results
Oct 21, 2023 04:25AM Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
Oct 19, 2023 07:15AM Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
Oct 18, 2023 07:15AM Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
Aug 29, 2023 04:01PM Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Aug 24, 2023 07:01PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2023 04:01PM Personalis Reports Second Quarter 2023 Financial Results
Aug 1, 2023 04:01PM Personalis to Participate at Upcoming Investor Conferences
Jul 25, 2023 04:01PM Personalis to Announce Second Quarter 2023 Financial Results
Jun 26, 2023 05:04PM Personalis (PSNL) Files Second Patent Infringement Suit Against Foresight Diagnostics
Jun 26, 2023 05:00PM Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
Jun 14, 2023 04:54AM Personalis, Inc. (PSNL) Appoints Kenneth J. Widder to its Board
Jun 13, 2023 07:01PM Dr. Kenneth J. Widder Joins Personalis Board of Directors
May 30, 2023 08:00AM Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
May 16, 2023 08:00AM Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
May 3, 2023 04:01PM Personalis Reports First Quarter 2023 Financial Results
May 2, 2023 08:03AM Personalis, (PSNL) ABRCC and Criterium Announce Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
May 2, 2023 08:00AM Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
Apr 19, 2023 04:01PM Personalis to Announce First Quarter 2023 Financial Results
Apr 5, 2023 04:01PM Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Apr 5, 2023 08:45AM Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
Mar 22, 2023 08:55AM Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
Mar 7, 2023 08:56AM Personalis (PSNL) will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement
Mar 7, 2023 08:55AM Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Mar 2, 2023 04:06PM Personalis, Inc. (PSNL) Appoints Christopher Hall as CEO
Mar 2, 2023 04:05PM Personalis Appoints Christopher Hall as Chief Executive Officer
Feb 23, 2023 04:01PM Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 9, 2023 04:01PM Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
Feb 6, 2023 04:01PM Personalis to Participate at Upcoming Investor Conferences
Feb 3, 2023 08:46AM Personalis (PSNL), Moderna (MRNA) Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Feb 3, 2023 08:45AM Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Jan 4, 2023 04:05PM Personalis, Inc. (PSNL) Prelim. Q4 Revenue Tops Consensus
Jan 4, 2023 04:01PM Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
Dec 16, 2022 04:05PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 14, 2022 04:02PM Personalis Announces CEO Retirement and Transition
Nov 30, 2022 08:55AM Personalis, Inc. (PSNL) and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Nov 30, 2022 08:55AM Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Nov 21, 2022 04:01PM Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
Nov 7, 2022 04:05PM Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Nov 2, 2022 04:01PM Personalis Reports Third Quarter 2022 Financial Results
Oct 31, 2022 04:16PM Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
Oct 19, 2022 04:01PM Personalis to Announce Third Quarter 2022 Financial Results
Oct 4, 2022 09:00AM Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
Aug 30, 2022 04:01PM Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 17, 2022 04:15PM Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
Aug 16, 2022 04:05PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2022 08:55AM Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
Aug 4, 2022 04:01PM Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
View More Recent Stories View Older Stories